Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine Dosing for Acute Pain in ED
NCT03896230Phase 4Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- May 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ketamine in acute pain (3 arms), sponsored by Hackensack Meridian Health. Primary endpoint: Numerical Rating Scale (NRS) Pain Score at 2 hours. Started May 2019; status: terminated.
02
Drugs
ketamine
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT03896230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896230.